MRS7145

**MRS7145** is a photoactive, light-operated small molecule drug designed as a selective antagonist of the *adenosine A2A receptor* for potential management of neurodegenerative movement disorders, primarily Parkinson’s disease. It is a derivative of SCH442416, specifically engineered by blocking the 5-amino position of SCH442416 with coumarin, making it inactive until activated by exposure to violet light (405 nm). Upon irradiation, MRS7145 is uncaged in targeted neural tissue (e.g., the dorsal striatum) and acts to block adenosine A2A receptor function, which physiologically leads to enhanced dopamine activity (pro-dopaminergic effect). This modality allows precise spatiotemporal control over drug activation, aiming to reduce off-target effects and enable site-specific therapeutic response. Preclinical animal studies show that photoactivation of MRS7145 increases locomotor activity and can reverse Parkinsonian symptoms, indicating potential efficacy for the treatment of movement disorders[1][3][5].